Investigational therapy ANVS401 (also known as Posiphen) reversed gastrointestinal dysfunction linked to early Parkinson’s in two mouse models of the disease. Results of the study, “Translational inhibition of α-synuclein by Posiphen normalizes distal colon motility in transgenic Parkinson mice,” were published in…
While there are few silver linings to the cloud created by COVID-19, the pandemic that has killed tens of thousands, hobbled economies worldwide and drove millions to quarantine in their homes, one may be a new appreciation of telemedicine. “If something good could come out of this crisis, it’s that…
The U.S. Food and Drug Administration (FDA) has approved Ongentys (opicapone) as an oral, add-on daily treatment for Parkinson’s disease patients experiencing off periods while on a levodopa/carbidopa regimen. The approval is for 25 mg and 50 mg capsules, either taken once a day. It comes after…
FFF Enterprises and Bionews announced today that both rare and orphan disease advocates are joining forces to provide patients with resources to help them connect as a community and continue to manage their health during this time when many are finding themselves alone. Recognized as the nation’s leading supplier of…
Nitrome Biosciences has raised $38 million in Series A financing to advance its lead program toward clinical trials for Parkinson’s disease (PD) and other age-related disorders. “This financing will enable Nitrome to advance our mission of impacting the lives of patients with neurodegenerative and other age-related diseases,” said…
MedRhythms, focused on creating treatments that incorporate music to aid people with walking problems due to neurological disorders, announced the issue of a new U.S. patent covering the audio engine of its digital therapeutics platform. The patent awarded by the United States Patent and Trademark Office is called “Enhancing…
A pilot study in Sweden shows the feasibility of testing how exercise benefits neuroplasticity — the brain’s ability to adjust and make new connections in response to stimuli or damage — in people with Parkinson’s disease, making a larger and more scientifically rigorous clinical trial possible. An ability to replicate…
Prasinezumab (PRX002/RG7935), an antibody designed to eliminate the toxic clumps of alpha-synuclein in Parkinson’s disease patients, did not lessen the progression of motor and non-motor symptoms over one year, compared with a placebo, findings from a Phase 2 clinical trial show. While the results mean that…
Despite being safe, spinal cord stimulation does not lead to significant improvements in mobility in patients with advanced Parkinson’s disease, including those taking levodopa, a prospective trial has found. The trial findings were reported in the study, “Spinal Cord Stimulation for Very Advanced Parkinson’s Disease:…
In observance of Parkinson’s Awareness Month, the World Parkinson Coalition is launching its first WPC Care Partner Virtual Panel Series to highlight and address caregiver challenges. The four-part online series, offering support and guidance to caregivers and family members, begins on Tuesday, April 28. Presenters include experts in…
Get regular updates to your inbox.
